ORIGINAL RESEARCH: Heparin and Derivatives a New and Possible Treatment of Alzheimer’s Disease
DOI:
https://doi.org/10.12970/2310-8231.2017.05.08Keywords:
Psychiatric disorder, heparin, non-anticoagulant properties, clinical response, targeted drug.Abstract
Our finding of the ability of heparin sulfate to control an psychiatric disorder as the onset of an acute myocardial infarction in elderly patients, led us to use this drug in Alzheimer‘s disease. A 78-year-old female patient with Alzheimer ‘s disease (AD) in moderate stage, was the first case that received heparin sulfate; initial dose of 10000 Uds, in 500 mls of 5% Dextrosa for IV inyection, weekly; demonstrating a significant improvement several hours after the initial treatment, in the cognitive impairment, especially in the memory and spatial orientation. Subsequently, five patients with AD received heparin having similar benefitial effect. We reported for the first time in the literature, both the atypical presentation of a myocardial infarction, controlled by heparin and, the effective response of Alzheimer’s disease after received this drug [3, 4].
In conclusion, the initial results showed that the non-anticoagulant action of heparin and derivatives is effective for Alzheimer’s disease which could be a targeted drug for this disease.
References
FDA US Food & Drug Administration. Targeted Drug Development: Why are many Disease Lagging Behind? Pages last updated 07-16-2015.
Obryant SE, Mielke MM, Rissman RA, et al. Bood-based biomarkers in Alzheimer’s disease: Current state of science and novel collaborative paradigm for advancing from discovery to clinic 2017; 13(1): 45-58.
Gomez-Valdes A. Mental disorder as the onset of acute myocardial infarction. Cuban Journal of Medicine 1972; 11: 330-340.
Gomez-Valdes A/ Trastornos mentales como expression inicial del infarto agudo del miocardio. Revista del Hospital Psiquiatrico de la Habana 1972; XIII(2).
Alcantar NA, Jimenez J, Morgan D. Direct measurement of adhesive forces in amyloid beta peptide structures. J of Alzheimer & Dementia 2005; 1(1): 511.
Chon JH, Chaikof EL. Soluble heparin-binding peptides regulate chemokinesis and cell adhesive forces. Am J Physiol 2001; 280(6): C1394-402.
Chaikiadaki G, Nikitovic D, Berdiaki A, et al. Heparin plays a key regulatory role via p53/FAK-dependent signaling in melanoma cell adhesion and migration. IUMB life 2011; 63(2): 119-19.
Chaikiadaki G, Nikitovic D, Katonis P, et al. Low molecular weight inhibits melanoma cell adhesion and migration through a PKCa/JNK signaling pathway inducing actin cytoskeleton changes 2011; 312(2): 235-44.
Thomton C, Bright NJ, Sastre M, et al. AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem J 2011; 434(3): 503-12.
Domise M, Dedier S, Marinangeli C. et al. AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep 2016; 10. 1038/ScRep 26750
Edward Y. Anti-inflammatory effects of heparin and related compounds. Thrombosis Research 2008; 122(6): 743-752.
Yamamoto S, Babazada H, Sakai S, et al. Anti-inflammatory effect of self- assembling glycol-split glycosaminoglycanstearylamine conjugates in lipopolysaccharide-stimulated macrophages 2017; 40(4): 540-45.
